IMMUNOHISTOCHEMICAL EXPRESSION OF HAX1 IN INVASIVE DUCTAL CARCINOMA OF THE BREAST AND CORRESPONDING LYMPH NODE METASTASES. | ||||
| Minia Journal of Medical Research | ||||
| Articles in Press, Accepted Manuscript, Available Online from 08 January 2024 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjmr.2024.144974.1091 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Dina Thabit  1; Fatma El Zahraa Ammar Mohamed2; Mariana Gayyed3; Heba Mohamed Tawfik4; Salwa Teleb2
| ||||
| 1pathology departement, Faculty of Medicine, Minia university, Minia, Egypt | ||||
| 2Pathology department, Minia University, Minia, Egypt. | ||||
| 336 Moustafa Fahmy street | ||||
| 4Pathology department, Minia University, Minia, Egypt | ||||
| Abstract | ||||
| Background: HAX1 protein comprises a family of ubiquitously expressed proteins ranging in size from ∼26 to ∼35 kDa that result from complex alternative splicing events of the single HAX-1 gene. Hax1 acts as antiapoptotic protein through different mechanisms. Moreover, HAX1 enhances cellular invasion and migration through different pathways. Aim: This study aimed to evaluate the clinical significance of HAX1 expression in invasive ductal carcinoma of the breast and in corresponding lymph node metastasis. Materials and methods: The expression of HAX1 was examined in 70 tumor tissues plus 54 paraffin blocks of corresponding lymph node metastasis by immunohistochemistry. Results: The association between expression of this marker and clinicopathological parameters was analyzed. HAX1 was highly expressed in 47.1% of the cases. HAX1 was positively correlated with larger tumor size (p=0.004), higher grade tumors (P = 0.029), advanced tumor stage (p=0.001), more lymph node involvement (p= 0.028), poor Nottingham prognostic index (P=0.008), PR negativity (p=0.031), HER2 negativity (p=0.024), high Ki67 index (p=0.029) and distant metastasis (p=0.002). As regard HAX1 expression in primary tumor and corresponding lymph node metastasis, 87% of pairs revealed a concordance between the primary tumor and corresponding lymph node metastasis and only 7 cases (13%) were nonconcordant and the results were statistically significant (p=0.001). Conclusion: These findings suggest that HAX1 expression can be considered as a poor prognostic and therapeutic marker for targeted therapy of breast cancer patients. | ||||
| Keywords | ||||
| HAX1; breast cancer; immunohistochemistry | ||||
|
Statistics Article View: 33 |
||||
